Ibsrela (Tenapanor)

Generic Name

Tenapanor

Brand Names

Ibsrela, Xphozah

FDA approval date: September 12, 2019

Classification: Sodium-Hydrogen Exchanger 3 Inhibitor

Form: Tablet

What is Ibsrela (Tenapanor)?

IBSRELA is indicated for treatment of irritable bowel syndrome with constipation in adults. IBSRELA is a sodium/hydrogen exchanger 3 inhibitor indicated for treatment of irritable bowel syndrome with constipation in adults.

Approved To Treat

Irritable Bowel Syndrome (IBS)

Top Global Experts

Save this treatment for later

Not sure about your diagnosis?

Check Your Symptoms

Related Clinical Trials

An Open-label, Single Center Study Assessing Tenapanor as a Non-CFTR-mediated Treatment of CF-related Constipation in People With CF.

Enrollment Status: Recruiting

Publish Date: March 18, 2026

Intervention Type: Drug

Study Phase: Phase 3

Summary: Tenapanor is the newest FDA-approved drug for IBS with constipation (IBS-C). This study seeks to understand tenapanor as a treatment for cystic fibrosis-related constipation (CFrC) in CF patients. Participants will ingest one 50 mg tablet of tenapanor, twice daily, for a 4-week treatment period. They will also complete three questionnaires, the PAC-SYM, PAC-QoL, and IBS-SSS, and daily diaries to c...

A 26-Week, Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety and Efficacy of Tenapanor for the Treatment of Chronic Idiopathic Constipation (CIC) in Adults

Enrollment Status: Recruiting

Publish Date: March 17, 2026

Intervention Type: Drug

Study Phase: Phase 3

Summary: This is a 26-week, multi-center, randomized, double-blind, placebo-controlled study with a 4-week treatment-free Safety Follow-up period to assess the safety and efficacy of tenapanor (5 mg, 25mg, and 50 mg) in adult patients with Chronic Idiopathic Constipation (CIC) when administered twice daily for 26 consecutive weeks.

A 12-Week, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Assess the Safety and Efficacy of Tenapanor for the Treatment of Irritable Bowel Syndrome With Constipation (IBS-C) in Pediatric Patients 12 to Less Than 18 Years Old

Enrollment Status: Recruiting

Publish Date: January 12, 2026

Intervention Type: Drug

Study Phase: Phase 3

Summary: This is a randomized, double-blind, placebo-controlled study to assess the efficacy, safety and tolerability of tenapanor (25 mg and 50 mg) in pediatric patients (≥12 and \<18 years old) with IBS-C when administered twice daily (BID) for 12 consecutive weeks.

View All Clinical Trials